The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Advances deployment of mRNA technology across vaccines and therapeutics development
This robust growth has come despite the raging pandemic for most part of the quarter
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Subscribe To Our Newsletter & Stay Updated
